Gilbert Cisneros Acquires Boston Scientific Shares

Gilbert Cisneros purchased Boston Scientific shares valued between $1,001 and $15,000.

Written by Opentrades · Published Jun 12, 2026, 9:21 PM EDT · Updated Jun 13, 2026, 2:10 AM EDT

Key Points

Gilbert Cisneros, a member of the U.S. House, bought Boston Scientific shares valued between $1,001 and $15,000 on May 11, 2026.
Boston Scientific, trading on the NYSE under BSX, has a market cap of $69.7 billion and a P/E ratio of 19.63.
Analysts recently maintained positive ratings on Boston Scientific, with price targets ranging from $55 to $89.

Congressional trading track record

Gilbert Cisneros vs. the S&P 500

YTD return -1.4% hypothetical

All-time return -1.0% S&P 500 +93.0%

vs. S&P 500 -94.0% behind the index

Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.

On May 11, 2026, Gilbert Cisneros, a member of the U.S. House, bought shares of Boston Scientific Corporation, trading under the ticker BSX on the NYSE. The transaction was valued between $1,001 and $15,000, according to the STOCK Act disclosure filed on June 9, 2026.

Boston Scientific Stock Snapshot

Shares of NYSE:BSX traded near $46.99 at the time of the report. Boston Scientific has a market cap of about $69.7 billion. The company maintains a P/E ratio of 19.63 and a forward P/E of 12.59, indicating investor expectations for future earnings. Its beta is 0.559, suggesting lower volatility compared to the market. The stock has ranged from a 52-week low of $45.99 to a high of $109.50, with a 50-day moving average of $56.54 and a 200-day moving average of $82.70.

Recent Earnings

Boston Scientific reported revenue of $20.61 billion, with a growth rate of 11.6%. The company achieved a net margin of 17.29% and a return on equity of 14.66%. Investors can expect the next earnings report on July 29, 2026.

Analysts Set New Price Targets

Several analysts have maintained their positive outlook on Boston Scientific. On June 4, 2026, Truist Securities maintained a 'buy' rating with a price target of $64. BTIG also kept a 'buy' rating, targeting $65, while Canaccord Genuity set a target of $70 on June 1, 2026. The consensus among 30 analysts is a 'strong buy' with a mean target price of $78.17.

About Boston Scientific

Boston Scientific Corporation, headquartered in Marlborough, Massachusetts, is a major player in the healthcare sector, specifically in medical devices. Under the leadership of CEO Michael F. Mahoney, the company develops and markets a wide range of products for medical specialties worldwide. With approximately 59,000 employees, Boston Scientific operates in MedSurg and Cardiovascular segments, providing devices for gastrointestinal, urological, cardiovascular, and neurological treatment.

Bottom Line

Investors often monitor stock trades by politicians like Gilbert Cisneros to gauge potential interest or insights. His recent purchase of Boston Scientific shares reflects a personal financial decision. It's important to note that these disclosures are made after the fact and don't necessarily reflect current holdings.